echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The marketing application of Shandong New Era Metformin Hydrochloride Sustained-Release Tablets was approved

    The marketing application of Shandong New Era Metformin Hydrochloride Sustained-Release Tablets was approved

    • Last Update: 2022-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      On April 15, NMPA released the latest drug approval information, and Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved
    .
    In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
    The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
    .
     
      Figure 1: Shandong New Times Pharmaceutical's latest approved product information
      Source: NMPA official website
     
      Metformin is a first-line drug for the treatment of type 2 diabetes.
    According to the data from Minet.
    com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
    The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
    2 billion yuan
    .
     
      Figure 2: Approved diabetes drugs by Shandong New Era Pharmaceuticals
      Source: new version database of Minet
     
      Shandong New Times Pharmaceutical has won miglitol tablets, glimepiride dropping pills and lipoic acid injection in the field of diabetes medication, among which glimepiride dropping pills are the first imitations in China, while miglitol tablets, In 2020, the sales volume of lipoic acid injection in public medical institutions in China will reach 500 million yuan and 1.
    3 billion yuan
    .
     
      Figure 3: Diabetes drugs reported by Shandong New Era Pharmaceuticals and under review
      Source: new version database of Minet
     
      According to data from Minet.
    com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
    This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
    product, worth looking forward to
    .
     
      Source: NMPA official website, Minet database
     
      Note: The review data statistics are as of April 15.
    If there are any omissions, please correct me!
      On April 15, NMPA released the latest drug approval information, and Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved
    .
    In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
    The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
    .
     
      Figure 1: Shandong New Times Pharmaceutical's latest approved product information
      Source: NMPA official website
     
      Metformin is a first-line drug for the treatment of type 2 diabetes.
    According to the data from Minet.
    com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
    The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
    2 billion yuan
    .
     
      Figure 2: Approved diabetes drugs by Shandong New Era Pharmaceuticals
      Source: new version database of Minet
     
      Shandong New Times Pharmaceutical has won miglitol tablets, glimepiride dropping pills and lipoic acid injection in the field of diabetes medication, among which glimepiride dropping pills are the first imitations in China, while miglitol tablets, In 2020, the sales volume of lipoic acid injection in public medical institutions in China will reach 500 million yuan and 1.
    3 billion yuan
    .
     
      Figure 3: Diabetes drugs reported by Shandong New Era Pharmaceuticals and under review
      Source: new version database of Minet
     
      According to data from Minet.
    com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
    This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
    product, worth looking forward to
    .
     
      Source: NMPA official website, Minet database
     
      Note: The review data statistics are as of April 15.
    If there are any omissions, please correct me!
      On April 15, NMPA released the latest drug approval information, and Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved
    .
    In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
    The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
    .
     
      Figure 1: Shandong New Times Pharmaceutical's latest approved product information
      Source: NMPA official website
     
      Metformin is a first-line drug for the treatment of type 2 diabetes.
    According to the data from Minet.
    com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
    The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
    2 billion yuan
    .
    hospital hospital hospital
     
      Figure 2: Approved diabetes drugs by Shandong New Era Pharmaceuticals
      Source: new version database of Minet
     
      Shandong New Times Pharmaceutical has won miglitol tablets, glimepiride dropping pills and lipoic acid injection in the field of diabetes medication, among which glimepiride dropping pills are the first imitations in China, while miglitol tablets, In 2020, the sales volume of lipoic acid injection in public medical institutions in China will reach 500 million yuan and 1.
    3 billion yuan
    .
     
      Figure 3: Diabetes drugs reported by Shandong New Era Pharmaceuticals and under review
      Source: new version database of Minet
     
      According to data from Minet.
    com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
    This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
    product, worth looking forward to
    .
     
      Source: NMPA official website, Minet database
     
      Note: The review data statistics are as of April 15.
    If there are any omissions, please correct me!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.